BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19766386)

  • 1. Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept.
    Sherif A; Hasan MN; Marits P; Karlsson M; Winqvist O; Thörn M
    Eur Urol; 2010 Jul; 58(1):105-11. PubMed ID: 19766386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perilymphatic injections of cytokines: a new tool in active cancer immunotherapy. Experimental rationale and clinical findings.
    Forni G; Giovarelli M; Jemma C; Bosco MC; Caretto P; Modesti A; Santoni A; Forni M; Cortesina G; de Stefani A
    Ann Ist Super Sanita; 1990; 26(3-4):397-409. PubMed ID: 2151108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of immune responses against urinary bladder cancer in sentinel lymph nodes.
    Marits P; Karlsson M; Sherif A; Garske U; Thörn M; Winqvist O
    Eur Urol; 2006 Jan; 49(1):59-70. PubMed ID: 16321468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
    de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
    Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
    Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
    J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
    Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
    Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
    Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
    Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of lymph node density in predicting survival of patients with lymph node metastases after radical cystectomy: a multi-institutional study.
    Osawa T; Abe T; Shinohara N; Harabayashi T; Sazawa A; Kubota K; Matsuno Y; Shibata T; Shinno Y; Kamota S; Minami K; Sakashita S; Kumagai A; Mori T; Nonomura K
    Int J Urol; 2009 Mar; 16(3):274-8; discussion 278. PubMed ID: 19087211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.
    Steven K; Poulsen AL
    J Urol; 2007 Oct; 178(4 Pt 1):1218-23; discussion 1223-4. PubMed ID: 17698113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer.
    Azumi M; Kobayashi H; Aoki N; Sato K; Kimura S; Kakizaki H; Tateno M
    J Urol; 2010 May; 183(5):2036-44. PubMed ID: 20303532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes.
    Boudreaux KJ; Chang SS; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Clark PE
    Cancer; 2009 Feb; 115(4):770-5. PubMed ID: 19152431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder cancer.
    Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Inoue Y; Noguchi H; Honda N
    Oncol Rep; 2007 Jul; 18(1):3-7. PubMed ID: 17549338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Radical cystectomy for superficial tumors in the BCG era].
    Huguet Pérez J; Palou J; Millán Rodríguez F; Villavicencio Mavrich H; Rodríguez JV
    Arch Esp Urol; 2002; 55(1):50-6. PubMed ID: 11957752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.